Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

2022142 citationsJournal Articlegreen Open Access

Authors

Sintilimab plus anlotinib as second-line or later therapy is efficacious and safe for patients with advanced CA who have failed prior chemotherapy.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 40, Issue 16, pp. 1795-1805

Field-Weighted Citation Impact: 14.23